<DOC>
	<DOCNO>NCT00441246</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy Mucinex D tablet provide symptom relief administer adjunct antibiotic therapy patient acute respiratory infection .</brief_summary>
	<brief_title>Phase 4 Study - Mucinex D Adjunct Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<criteria>Ages Eligible Study : 18 75 year , Genders Eligible Study : Both Adult patient present physician 's office symptom diagnostic acute respiratory infection , bronchitis rhinosinusitis ; clinical diagnosis acute respiratory infection , meet physician 's usual diagnostic criterion practice prescription oral antibiotic . The investigator evaluate patient total seven criterion inclusion . Have chronic , recur respiratory sign symptom , allergic rhinitis chronic bronchitis , , investigator 's opinion , would confound interpretation symptom rating acute respiratory infection ; The Investigator evaluate patient twelve additional criterion exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Acute Respiratory Infection</keyword>
	<keyword>Bronchitis</keyword>
	<keyword>Rhinosinusitis</keyword>
</DOC>